Label: L-METHYL-MC- levomefolate calcium, riboflavin, pyridoxine hydrochloride, and cyanocobalamin tablet, coated

  • Category: MEDICAL FOOD

Drug Label Information

Updated September 17, 2015

If you are a healthcare professional or from the pharmaceutical industry please visit this version.


    A medical food for the dietary management of hyperhomocysteinemia.

  • Description

    Each round coated blue colored tablet contains:

    Dietary Ingredients:
    L-methylfolate Calcium6 mg
    Riboflavin5 mg
    Pyridoxine (as Pyridoxine HCl)50 mg
    Cyanocobalamin1 mg


    Microcrystalline Cellulose, Pyridoxine HCl,Opadry II Blue #40L10890 (Polydextrose, Hypromellose HPMC 2910, FD&C Blue #1 Aluminum Lake, Triacetin, Titanium Dioxide, Peg 8000). Stearic Acid (Vegetable Source), Croscarmellose Sodium, L-methylfolate Calcium, Riboflavin, Silicon Dioxide, Magnesium Stearate (Vegetable Source), Opadry II Clear #Y-19-7483, (Hypromellose HPMC 2910, Maltodextrin, Peg 400), Cyanocobalamin.

    L-Methyl-MC Tablets do not contain sugar, lactose, yeast or gluten.

  • Indication and Usage

    L-Methyl-MC Tablets are indicated for the distinct nutritional requirements of individuals under medical supervision for hyperhomocysteinemia; with particular emphasis for individuals diagnosed with or at risk for mild to moderate: cognitive impairment1, vascular dementia2, or Alzheimer's disease3.

  • Precautions

    Folates, when administered as a single agent in doses above 0.1mg daily, may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations remain progressive. The 1 mg of cyanocobalamin contained in L-Methyl-MC Tablets has been shown to provide an adequate amount of cyanocobalamin to address this precaution4. A safe upper limit of 100 mg per day has been established for the unsupervised medical use of pyridoxine. Consider all sources of pyridoxine supplementation when prescribing L-Methyl-MC Tablets.

  • Adverse Reactions

    While allergic sensitization has been reported following both oral and parenteral administration of folic acid, allergic sensitization has not been reported with the use of L-Methylfolate Calcium. Paresthesia, somnolence, nausea and headaches have been reported with pyridoxine. Mild transient diarrhea, polycythemia vera, itching, transitory exanthema and the feeling of swelling of the entire body has been associated with cyanocobalamin. Transient headaches have been reported infrequently with the use of L-Methyl-MC Tablets. If headaches should occur with the use of L-Methyl-MC Tablets consult with your medical practitioner.

  • Contraindications

    Known hypersensitivity to any of the components in the product is a contraindication.

  • Drug Interactions

    L-Methyl-MC Tablets added to other drugs

    High dose folic acid may result in decreased serum levels for pyrimethamine and first-generation anticonvulsants (carbamazepine, fosphenytoin, phenytoin, phenobarbital, primidone, valproic acid, valproate). This may possibly reduce first generation anticonvulsants effectiveness and/or increasing the frequency of seizures in susceptible patients. While the concurrent use of folic acid and first generation anticonvulsants or pyrimethamine may result in decreased efficacy of anticonvulsants, no such decreased effectiveness has been reported with the use of L-methylfolate. Nevertheless, caution should be used when prescribing L-METHYL-MC TABLETS among patients who are receiving treatment with first generation anticonvulsants or pyrimethamine. Pyridoxine should not be given to patients receiving the drug levodopa, because the action of levodopa is antagonized by pyridoxine. However, pyridoxine may be used concurrently in patients receiving a preparation containing both carbidopa and levodopa. Capecitabine (Xeloda®) toxicity may increase with the addition of leucovorin (5-formyltetrahydrofolate) (folate).

    Drugs added to L-METHYL-MC TABLETS

    Antibiotics may alter the intestinal microflora and may decrease the absorption of cyanocobalamin. Cholestyramine, colchicines or colestipol may decrease the enterohepatic reabsorption of cyanocobalamin. Metformin, para-aminosalicylic acid and potassium chloride may decrease the absorption of cyanocobalamin. Nitrous oxide can produce a functional cyanocobalamin deficiency. Several drugs are associated with lowering serum folate levels or reducing the amount of active folate available. First generation anticonvulsants (carbamazepine, fosphenytoin, phenytoin, phenobarbital, primidone, valproic acid, valproate) and lamotrigine (a second-generation anticonvulsant) may decrease folate plasma levels. Information on other second-generation anticonvulsants impact on folate levels is limited and cannot be ruled out. Methotrexate, alcohol (in excess), sulfasalazine, cholestyramine, colchicine, colestipol, L-dopa, methylprednisone, NSAIDs (high dose), pancreatic enzymes (pancrelipase, pancratin), pentamidine, pyrimethamine, smoking, triamterene, and trimethoprim may decrease folate plasma levels. Warfarin can produce significant impairment in folate status after a 6 month therapy.

  • Patient Information

    L-Methyl-MC Tablets is a medical food for use only under medical supervision.

  • Dosage and Administration

    Usual adult dose is one to two tablets daily or as directed by your medical practitioner. L-Methyl-MC Tablets is not recommended for use with children under the age of twelve.

  • How Supplied

    Available as a round coated blue colored tablet. Debossed with "V360" on one side and blank on the other. Commercial product is supplied in bottles of 90 tablets (76439-360-901). Use under medical/physician supervision.

    Virtus Pharmaceuticals, LLC does not represent this product code to be a National Drug Code (NDC) number. Instead, Virtus Pharmaceuticals, LLC has assigned a product code formatted according to standard industry practice to meet the formatting requirements of pharmacy and health insurance computer systems.


    Store at controlled room temperature 15ºC to 30ºC (59ºF to 86ºF) (See USP).

  • Patents

    Some or all of the following-patents may apply:

    U.S. Patent No. 5,563,126
    U.S. Patent No. 5,795,873
    U.S. Patent No. 5,997,915
    U.S. Patent No. 6,011,040
    U.S. Patent No. 6,207,651
    U.S. Patent No. 6,254,904
    U.S. Patent No. 6,297,224
    U.S. Patent No. 6,528,496
    and other pending patent applications.

  • References

    1 Lehmann M, Regland B, Blennow K, and Gottfries CG: Vitamin B12-B6-Folate Treatment Improves Blood-Brain Barrier Function in Patients with Hyperhomocysteinaemia and Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders 2003;16:145-150.

    2 Nilsson K, Gustafson L, and Hultberg B: Improvement of cognitive functions after cobalamin/folate supplementation in elderly patients with dementia and elevated plasma homocysteine. International Journal of Geriatric Psychiatry 2001;16:609-614.

    3 Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PWF, and Wolf PA: Plasma Homocysteine As A Risk Factor For Dementia And Alzheimer's Disease. New England Journal of Medicine 2002:Vol346, No. 7:476-483.

    4 Lederle FA: Oral cobalamin for pernicious anaemia: medicine's best kept secret. JAMA 1991;265:94-95.


    Manufactured for:
    Virtus Pharmaceuticals, LLC
    Tampa, FL 33619

    Revised 11/14

  • PRINCIPAL DISPLAY PANEL - 90 Tablet Bottle Label





    90 Tablets

    Made in the USA

    PRINCIPAL DISPLAY PANEL - 90 Tablet Bottle Label
    levomefolate calcium, riboflavin, pyridoxine hydrochloride, and cyanocobalamin tablet, coated
    Product Information
    Product TypeMEDICAL FOODItem Code (Source)NHRIC:76439-360
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Levomefolate Calcium (UNII: A9R10K3F2F) (Levomefolic Acid - UNII:8S95DH25XC) Levomefolate Calcium6 mg
    Riboflavin (UNII: TLM2976OFR) (Riboflavin - UNII:TLM2976OFR) Riboflavin5 mg
    Pyridoxine Hydrochloride (UNII: 68Y4CF58BV) (Pyridoxine - UNII:KV2JZ1BI6Z) Pyridoxine Hydrochloride50 mg
    Cyanocobalamin (UNII: P6YC3EG204) (Cyanocobalamin - UNII:P6YC3EG204) Cyanocobalamin1 mg
    Inactive Ingredients
    Ingredient NameStrength
    Cellulose, Microcrystalline (UNII: OP1R32D61U)  
    Polydextrose (UNII: VH2XOU12IE)  
    FD&C Blue No. 1 (UNII: H3R47K3TBD)  
    Aluminum Oxide (UNII: LMI26O6933)  
    Triacetin (UNII: XHX3C3X673)  
    Titanium Dioxide (UNII: 15FIX9V2JP)  
    Polyethylene Glycol 8000 (UNII: Q662QK8M3B)  
    Stearic Acid (UNII: 4ELV7Z65AP)  
    Croscarmellose Sodium (UNII: M28OL1HH48)  
    Silicon Dioxide (UNII: ETJ7Z6XBU4)  
    Magnesium Stearate (UNII: 70097M6I30)  
    Maltodextrin (UNII: 7CVR7L4A2D)  
    Polyethylene Glycol 400 (UNII: B697894SGQ)  
    Product Characteristics
    ColorBLUEScoreno score
    FlavorImprint Code V360
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NHRIC:76439-360-9090 in 1 BOTTLE
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    MEDICAL FOOD02/09/2015
    Labeler - Virtus Pharmaceuticals (969483143)